Amin Talati Wasserman Revenue and Competitors

Chicago, IL USA

Location

N/A

Total Funding

Legal

Industry

Estimated Revenue & Valuation

  • Amin Talati Wasserman's estimated annual revenue is currently $12.4M per year.(i)
  • Amin Talati Wasserman's estimated revenue per employee is $243,000

Employee Data

  • Amin Talati Wasserman has 51 Employees.(i)
  • Amin Talati Wasserman grew their employee count by -4% last year.

Amin Talati Wasserman's People

NameTitleEmail/Phone
1
PartnerReveal Email/Phone
2
PartnerReveal Email/Phone
3
PartnerReveal Email/Phone
4
PartnerReveal Email/Phone
5
PartnerReveal Email/Phone
6
Paralegal at Amin Talati WassermanReveal Email/Phone
7
PartnerReveal Email/Phone
8
Of CounselReveal Email/Phone
9
Associate AttorneyReveal Email/Phone
10
Administrative AssistantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$14.3M592%N/AN/A
#2
$0.3M2-50%N/AN/A
#3
$1258.4M37190%N/AN/A
#4
$640M1693-2%N/AN/A
#5
$6.9M32-3%N/AN/A
#6
$5.1M27-10%N/AN/A
#7
$4.7M254%N/AN/A
#8
$7.3M343%N/AN/A
#9
$1.2M9-25%N/AN/A
#10
$27.3M101N/AN/AN/A
Add Company

What Is Amin Talati Wasserman?

We are focused on the industries of food and beverages, nutritional supplements, cosmetics, and pharmaceuticals. We provide full legal services for the lifecycle of products aimed at improving the population’s health and wellness. Amin Talati Upadhye has gained renown for its work at the cutting edge of food and drug/FDA law, responding nimbly to rapid changes in the regulatory climate and the market place. We work with some of the most innovative products in this sphere, such as raw juices, nutraceuticals and hemp products: we counsel on regulatory compliance, product development, product launch, patent and trademark, and litigation and enforcement matters in these rapidly evolving areas. Our attorneys also work closely with pharmaceutical companies through the entire development pipeline, from prototype development and clinical trials with an eye towards gaining FDA approval, through eventual patent applications and possible challenges in court. We have developed a special renown in the representation of generic drug companies in Paragraph IV litigation: the process whereby companies challenge patents held by brand name companies in order to bring these important, often life-saving, medications to the market in generic forms. In addition to guiding our clients through the strategic development of new products through regulatory approvals to the marketplace, we advise on all post-launch processes as well to ensure labeling, advertising, safety and manufacturing compliance requirements. Where necessary we counsel on recalls, class actions and inspections, working closely with the firm’s Litigation team on enforcement actions, product seizures, Lanham Act claims and criminal actions.

keywords:N/A

N/A

Total Funding

51

Number of Employees

$12.4M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.2M51-28%N/A
#2
$6.2M51-12%$717.9M
#3
$12.4M514%N/A
#4
$9.4M51N/AN/A
#5
$11.6M510%N/A